Costa, H.Espirito Santo, M.Fernandes, R.Carvalho, D.Bispo, J.Guedes, J.Azevedo, P.Vinhas, H.Mimoso, J.Jesus, I.2025-01-032025-01-032023-111522-9645http://hdl.handle.net/10400.1/26563The use of aspirin in primary prevention (PP) remains a matter of international debate. In type 2 diabetes mellitus (DM2) patients with high/very high cardiovascular (CV) risk, low dose aspirin may be considered for PP (class IIb, evidence level A) in european guidelines in the absence of hemorrhagic contraindication.engconference object10.1093/eurheartj/ehad655.25640195-668X